MarketPeel
Insider Trading Intelligence
Pricing
…
JS

Jonathan Slonin

PCRX
CHIEF MEDICAL OFFICER · PACIRA BIOSCIENCES, INC. · CIK 0001875723
FILING MIX · LIFETIME34%/66%
BUYS
11
SELLS
21
TOTAL VALUE
$1.14M
COMPANIES
1
ACTIVE SINCE
Aug 2021
HOLDINGS NOW
218,912
AVG SELL PX
$26.17
TRADE KIND
SHOWING 32 / 32
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
12 backtested trades · 8 horizons · 7 pending
Forward-return performance of every backtestable P/S trade by Jonathan Slonin, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d12+66.67%-5.49%-1.02%-4.47%-2.99%—
14d12+50.00%-3.19%+0.21%-3.40%-2.73%—
30d12+58.33%-1.41%+1.11%-2.53%-3.65%—
60d12+58.33%-10.45%+2.05%-12.50%-4.46%—
90d12+75.00%-12.54%+0.30%-12.84%-10.83%—
180d12(1 pending)+72.73%-15.22%+5.74%-20.96%-24.54%—
1y12(2 pending)+60.00%-15.93%+15.55%-31.48%-42.20%—
2y12(4 pending)+75.00%-37.58%+38.35%-75.93%-79.67%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PCRX · 218,912.175 shares · as of Jun 3, 2026
056,725113,451170,176226,90120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 11 buys / 21 sellsCOVERAGE · 20 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Medical Officer
4,728$22.32$105.5K218,912.175Jun 3, 2026Jun 5, 2026 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
3,261$22.82$74.4K223,640.175Mar 17, 2026Mar 19, 2026 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
54,546——226,901.175Feb 11, 2026Feb 13, 2026 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Medical Officer
6,168$20.54$126.7K172,355.175Jan 30, 2026Feb 3, 2026 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Medical Officer
381$24.46$9.3K178,523.175Jan 2, 2026Jan 6, 2026 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
3,960$24.09$95.4K178,367.009Nov 17, 2025Nov 19, 2025 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Medical Officer
315$22.07$7.0K182,327.009Aug 1, 2025Aug 4, 2025 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Medical Officer
5,084$26.40$134.2K181,959.511Jun 3, 2025Jun 5, 2025 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
93,600——187,043.511Feb 1, 2025Feb 4, 2025 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
879$18.40$16.2K93,443.511Jan 6, 2025Jan 6, 2025 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Medical Officer
371$18.33$6.8K94,322.511Jan 2, 2025Jan 6, 2025 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
945$20.05$18.9K94,306.746Aug 2, 2024Aug 2, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Medical Officer
305$20.75$6.3K95,251.746Aug 1, 2024Aug 2, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
2,836$28.25$80.1K95,556.746Jul 2, 2024Jul 3, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Medical Officer
914$28.46$26.0K98,392.746Jul 1, 2024Jul 3, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
437.271$24.32$10.6K99,306.746Jun 28, 2024Jul 3, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
54,300——98,869.475Jun 12, 2024Jun 13, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
5,012$28.57$143.2K44,569.475Jun 11, 2024Jun 13, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Medical Officer
1,615$30.89$49.9K49,581.475Jun 3, 2024Jun 5, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
10,000——10,000Jan 3, 2024Jan 4, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
5,000——51,196.475Jan 2, 2024Jan 4, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Clinical Officer
490$37.87$18.6K36,323Jun 7, 2023Jun 7, 2023 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Clinical Officer
471$38.99$18.4K36,813Jun 6, 2023Jun 7, 2023 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Clinical Officer
308$55.70$17.2K37,079Aug 3, 2022Aug 5, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Clinical Officer
924$57.19$52.8K37,387Jul 5, 2022Jul 7, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
9,900——38,097Jun 8, 2022Jun 8, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASE
Chief Clinical Officer
24,800——24,800Jun 8, 2022Jun 8, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Clinical Officer
362$61.37$22.2K28,197Jun 6, 2022Jun 8, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
Chief Clinical Officer
2,000——35,500May 23, 2022May 25, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASE
Chief Clinical Officer
2,000$52.37$104.7K28,559May 23, 2022May 25, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
10,000——10,000Aug 3, 2021Aug 5, 2021 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
5,000——26,350Aug 3, 2021Aug 5, 2021 ↗View →
Other insiders · PCRX
Loading peer insiders…
About this filer
CIK 0001875723
ROLE
Chief Medical Officer
PRIMARY
PCRX
COMPANIES
1
ACTIVE SINCE
Aug 2021
MARKETPEEL · /INSIDER/0001875723DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback